Entera Bio closed at $3.11 on Nov 4, up 1.97%, 20.7% below its 52-week closing high. Volume of 291.8K shares was 0.51× its 20-day average (below normal).
Split-adjusted performance: +22.9% over one month, +148.8% over six months, +9.5% over one year.
Short interest was 5.5M shares at the Oct 15 settlement, up 130.9% from the prior report (3.5% of float, 7.2 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| ENTXEntera Bio | $3.11 | +1.97% | +148.8% | — | — | — | $540.9M | |
| RGNXREGENXBIO | $7.71 | +1.05% | −24.6% | +405.7% | 21.0% | — | $509.0M | Compare |
| FDMT4D Molecular Therapeutics | $12.28 | +2.76% | +17.9% | +25106.7% | −1929.0% | — | $678.4M | Compare |
| AURAAura Biosciences | $6.65 | +6.57% | −19.8% | — | — | — | $689.6M | Compare |
| CADLCandel Therapeutics | $9.05 | +2.61% | +18.6% | — | — | — | $692.5M | Compare |
| SLDBSolid Biosciences | $6.52 | +3.82% | −9.4% | — | — | — | $699.1M | Compare |
| EDITEditas Medicine | $2.72 | +4.62% | −14.3% | +232.3% | −153.3% | — | $417.7M | Compare |
| ALLOAllogene Therapeutics | $1.19 | +6.25% | −48.5% | — | −919.8% | — | $411.1M | Compare |
| ATTOAttovia Therapeutics | $15.60 | +2.16% | — | — | — | — | $712.2M | Compare |
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
